Hindustan Bio Sciences Ltd.
BSE: HINDBIO · Software Products
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Hindustan Bio Sciences Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Hindustan Bio Sciences Limited is a Hyderabad-based pharmaceutical and biotechnology company specialising in the manufacturing and marketing of formulations such as tablets, capsules, and injectables. The firm serves both human and veterinary medicine markets through its product portfolio and contract manufacturing services.
Business Model
The company generates revenue through the sale of pharmaceutical products across various therapeutic segments and by providing contract manufacturing services. It maintains a dual focus on domestic distribution and international exports.
Growth Outlook
Growth is expected to be driven by the expansion of its biotechnology research and development activities and the scaling of its contract manufacturing capabilities. The company aims to leverage its position in the Indian healthcare landscape to provide affordable medical solutions.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from domestic and international health authorities regarding manufacturing standards and product quality.
- Market Competition. As a small-cap entity, the firm faces intense competition from larger, well-capitalised pharmaceutical companies in both domestic and export markets.
- Supply Chain Volatility. Fluctuations in the cost and availability of active pharmaceutical ingredients (APIs) could adversely impact profit margins.
- Currency Risk. Exposure to international markets introduces risks associated with foreign exchange rate fluctuations affecting export revenues.
Start your research today
Unlock AI insights, financials, peers and live data on Hindustan Bio Sciences Ltd. and 5,000+ companies — free.
Peers · Software Products
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Hindustan Bio Sciences Ltd.HINDBIO | ₹9 Cr | — | — | — | -8.1% | — | — | +3.6% |
SubexSUBEXLTD | ₹1,019 Cr | 33.57 | 16.31 | 2.9% | 19.7% | 9.3% | 10.2% | +44.9% |
Unicommerce Esolutions LimitedUNIECOM | ₹980 Cr | 45.41 | 26.27 | — | 17.6% | 16.4% | 19.6% | -33.2% |
Quick Heal Technologies LimitedQUICKHEAL | ₹753 Cr | -72.26 | -122.63 | -6.6% | -2.4% | -2.4% | -4.7% | -52.0% |
IRIS Regtech SolutionsIRIS | ₹516 Cr | 4.11 | 26.20 | 6.1% | 14.1% | 90.7% | 11.2% | -30.2% |
ABM Knowledgeware LimitedABMKNO | ₹387 Cr | 29.94 | 19.88 | — | 21.4% | 5.1% | 7.0% | +16.4% |
As of Mar 2026
Financials
Hindustan Bio Sciences Ltd.
BSE: HINDBIO · Software Products
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Hindustan Bio Sciences Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Hindustan Bio Sciences Limited is a Hyderabad-based pharmaceutical and biotechnology company specialising in the manufacturing and marketing of formulations such as tablets, capsules, and injectables. The firm serves both human and veterinary medicine markets through its product portfolio and contract manufacturing services.
Business Model
The company generates revenue through the sale of pharmaceutical products across various therapeutic segments and by providing contract manufacturing services. It maintains a dual focus on domestic distribution and international exports.
Growth Outlook
Growth is expected to be driven by the expansion of its biotechnology research and development activities and the scaling of its contract manufacturing capabilities. The company aims to leverage its position in the Indian healthcare landscape to provide affordable medical solutions.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from domestic and international health authorities regarding manufacturing standards and product quality.
- Market Competition. As a small-cap entity, the firm faces intense competition from larger, well-capitalised pharmaceutical companies in both domestic and export markets.
- Supply Chain Volatility. Fluctuations in the cost and availability of active pharmaceutical ingredients (APIs) could adversely impact profit margins.
- Currency Risk. Exposure to international markets introduces risks associated with foreign exchange rate fluctuations affecting export revenues.
Start your research today
Unlock AI insights, financials, peers and live data on Hindustan Bio Sciences Ltd. and 5,000+ companies — free.
Peers · Software Products
As of Mar 2026